Tompkins Financial Corp Raises Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Tompkins Financial Corp lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 333.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 650 shares of the medical instruments supplier’s stock after acquiring an additional 500 shares during the period. Tompkins Financial Corp’s holdings in Becton, Dickinson and Company were worth $147,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Central Pacific Bank Trust Division grew its position in Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares during the last quarter. Birch Capital Management LLC grew its position in Becton, Dickinson and Company by 0.4% in the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock valued at $2,838,000 after buying an additional 48 shares during the last quarter. Radnor Capital Management LLC increased its stake in Becton, Dickinson and Company by 1.7% in the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 48 shares during the period. Finally, Umpqua Bank raised its position in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock worth $660,000 after buying an additional 49 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 8,747 shares of company stock worth $1,949,520. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

BDX stock opened at $236.23 on Friday. The firm has a 50 day moving average of $226.77 and a 200-day moving average of $232.51. The company has a market cap of $68.51 billion, a price-to-earnings ratio of 39.77, a PEG ratio of 1.69 and a beta of 0.39. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.42 earnings per share. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.76%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.